DexCom to collaborate with Elliott Management, name two new Board members

DexCom (DXCM) “announced key updates to its governance structure in conjunction with its upcoming 2026 Investor Day presentation that outlines a strategic and financial vision to best position the company for future growth. Dexcom and Elliott Investment Management have agreed to collaborate to identify two new independent members to join the Board of Directors. To this end, Dexcom has initiated a search focusing on leaders with MedTech leadership or lean operations experience. These directors, alongside the existing Board members, will provide additional oversight and support to management as the company embraces its significant long-term opportunity and global customer growth ambitions. With these appointments, the Board will have appointed six new independent directors since the beginning of 2023.”